Tirzepatide vs mazdutide: evidence, cost, and legality

Which is better, tirzepatide or mazdutide?

Both have human_rct evidence, but tirzepatide's is larger (SURMOUNT-1 alone enrolled 2,539 adults for 72 weeks), it is FDA approved for diabetes, obesity, and sleep apnea, and it can be prescribed today. Mazdutide's high dose US data are promising but come from a 179 person, 32 week phase 2 trial, it has no FDA approval or lawful US compounding pathway, and it has no reported cardiovascular outcomes trial. No trial has compared the two directly. [1] [4] [5] [8] [10]

How do tirzepatide and mazdutide compare?

Tirzepatide and Mazdutide compared by dimension
Dimension	TirzepatideFavored	Mazdutide
Mechanism [4] [8]	Dual GIP and GLP-1 receptor agonist.	Oxyntomodulin analog that activates GLP-1 and glucagon receptors; glucagon activity adds energy expenditure and liver fat oxidation.
Obesity trial evidence [1] [4] [5]	SURMOUNT-1 (2,539 adults, 72 weeks): 15.0%, 19.5%, and 20.9% at 5, 10, and 15 mg versus 3.1% on placebo.	GLORY-1 (610 Chinese adults, 48 weeks): 11.0% and 14.0% at 4 and 6 mg versus plus 0.3% on placebo. US phase 2 (179 adults, 32 weeks): 7.3%, 15.6%, and 18.1% at 3 to 6, 10, and 16 mg versus 0.9%.
Note: Cross-trial comparison only; populations, baseline BMI, and durations differ.
Type 2 diabetes evidence [2] [6]	SURPASS-2 (1,879 adults, 40 weeks): HbA1c minus 2.01 to minus 2.30 points, beating semaglutide 1 mg.	Phase 2 (250 Chinese adults, 20 weeks): HbA1c minus 1.41 to minus 1.67 points versus minus 1.35 with dulaglutide 1.5 mg.
Cardiovascular outcomes [3] [7]	SURPASS-CVOT versus dulaglutide in type 2 diabetes reported noninferiority in 2025.	No cardiovascular outcomes trial reported.
Side effects [1] [4] [6] [8]	Nausea up to 31%, diarrhea up to 23%, vomiting up to 12% at 15 mg in SURMOUNT-1; thyroid C-cell boxed warning.	Diarrhea 36%, decreased appetite 29%, nausea 23%, vomiting 14% in the diabetes phase 2 trial; discontinuation for adverse events 1.5% or less in GLORY-1; heart rate increase from glucagon activity.
Regulatory status (United States) [8] [9] [10] [13] [14]	FDA approved: Mounjaro (2022) and Zepbound (2023). Compounding allowance ended in early 2025 after the shortage resolved.	Not FDA approved; not a component of an approved drug and not on the 503A bulks list, so it cannot be compounded or dispensed in the US. It is approved in China for chronic weight management and type 2 diabetes, but a Chinese approval has no bearing on US legality.
WADA status [11]	Not on the WADA Prohibited List.	Unclear: prohibited under section S0 wherever it is not approved; athletes should confirm with their anti-doping organization.
Access and cost [10] [12]	Prescription at a retail pharmacy; Zepbound list about 1,059 USD per month, manufacturer vials roughly 349 to 499 USD.	No lawful US access outside a registered clinical trial; research chemical listings are not lawful for human use.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Tirzepatide and Mazdutide: grade, status, and cost
Attribute	Tirzepatide	Mazdutide
Class	Dual GIP and GLP-1 receptor agonist (39 amino acid peptide, acylated for once weekly dosing)	Dual agonist of the GLP-1 and glucagon receptors (oxyntomodulin analog, acylated, once weekly)
What it is	FDA approved weekly GIP and GLP-1 drug with 20.9% average weight loss at 15 mg in a 72 week randomized trial; beat semaglutide head to head.	GLP-1/glucagon dual agonist with 14% weight loss at 48 weeks in a Chinese phase 3 trial and 18% at 16 mg in a US phase 2; not FDA approved.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: Not eligible for compounding
Compounding	FDA approved products (Mounjaro May 2022, Zepbound November 2023). FDA declared the tirzepatide shortage resolved on December 19, 2024; compounding by 503A pharmacies had to stop by February 18, 2025 and by 503B outsourcing facilities by March 19, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit tirzepatide products. On April 30, 2026 FDA proposed not to include tirzepatide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.	Not FDA approved as of the last verification date. Because mazdutide is not a component of an FDA approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded or dispensed in the United States, and any product sold as mazdutide in the US is an unapproved drug. Its development and registration have centered on China, where the national drug regulator approved it for chronic weight management in adults (June 2025) and for type 2 diabetes (September 2025); those approvals do not make it legal to sell or compound in the US.
WADA	WADA: Not WADA prohibited	WADA: WADA status unclear
Routes	Subcutaneous injection once weekly (pen or single dose vial)	Subcutaneous injection once weekly
Typical cost	Manufacturer list price is up to 1,086.37 USD per fill for Zepbound and 1,112.16 USD for Mounjaro (checked 2026-09-22). Manufacturer self-pay Zepbound vials and KwikPen cost 299 USD per month at 2.5 mg, 399 at 5 mg, 499 at 7.5 mg, and 699 at 10 mg and above, with a 449 USD on-time refill offer for the 7.5 mg and higher KwikPen through 2026. With commercial insurance a savings card can bring a covered prescription to 25 USD, and eligible Medicare Part D enrollees pay 50 USD per month for the Zepbound KwikPen under the Medicare GLP-1 Bridge (July 2026 to December 2027). A study published in 2025 found compounded tirzepatide advertised at a median 330 USD for the first month during the shortage; compounding is now limited to patient specific needs.	Not available through licensed channels in the United States. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 27, 2026	Sep 27, 2026

Has tirzepatide been tested directly against mazdutide?

No published trial has compared tirzepatide and mazdutide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do tirzepatide and mazdutide cost?

Typical cost of Tirzepatide and Mazdutide
Dimension	Tirzepatide	Mazdutide
Typical cost	$275 to $1,112 per month	Not available through licensed channels in the United States. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Tirzepatide price by channel	Price index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is mazdutide stronger than tirzepatide?

There is no direct comparison. Tirzepatide 15 mg produced 20.9% weight loss at 72 weeks in SURMOUNT-1; mazdutide 16 mg produced 18.1% at 32 weeks in a smaller US phase 2 trial, and 6 mg produced 14.0% at 48 weeks in GLORY-1. Longer phase 3 data at high doses are needed before any ranking. [1] [4] [5]

How do they work differently?

Both activate the GLP-1 receptor. Tirzepatide adds GIP receptor activity, while mazdutide adds glucagon receptor activity, which raises energy expenditure and liver fat burning but can also raise heart rate. [4] [8]

Can I get mazdutide in the United States?

Not lawfully outside a clinical trial. It is not FDA approved, not a component of an approved drug, and not on the 503A bulks list, so pharmacies cannot compound it. [10]

Which is better for type 2 diabetes?

Tirzepatide has the stronger and broader evidence, including SURPASS-2 against semaglutide and SURPASS-CVOT against dulaglutide. Mazdutide lowered HbA1c by 1.41 to 1.67 points in a 20 week phase 2 trial, slightly more than dulaglutide, but has no US approval. [2] [3] [6]

Are either banned in sport?

Tirzepatide is not on the WADA Prohibited List. Mazdutide's status is unclear because it depends on whether it is approved anywhere; WADA section S0 prohibits substances without approval for human use, so athletes should treat it as prohibited unless told otherwise. [11]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 27). Tirzepatide vs mazdutide: evidence, cost, and legality. https://peptideagent.ai/compare/tirzepatide-vs-mazdutide
HTML link: <a href="https://peptideagent.ai/compare/tirzepatide-vs-mazdutide">Tirzepatide vs mazdutide: evidence, cost, and legality</a>, PeptideAgent, updated September 27, 2026.

Tirzepatide vs mazdutide

The short answer